NDLI: Augmentation of antidepressants with atypical antipsychotics: a review of the current literature.

Please wait, while we are loading the content...

Augmentation of antidepressants with atypical antipsychotics: a review of the current literature.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Philip, Noah S. Carpenter, Linda L. Tyrka, Audrey R. Price, Lawrence H.
Description	Country affiliation: United States Author Affiliation: Philip NS ( Mood Disorders Research Program, Butler Hospital, Providence, RI 02906, USA.)
Abstract	Studies have found that a large percentage of depressed patients may have limited response and remission rates when treated with traditional antidepressants. Options for augmenting antidepressant treatment include buspirone, lithium, and triiodothyronine. There are also increasing data concerning the use of atypical antipsychotics as augmenting agents in the treatment of unipolar, nonpsychotic, treatment-resistant depression. Aripiprazole has recently received an indication from the U.S. Food and Drug Administration (FDA) for adjunctive treatment in unipolar, nonpsychotic depression, the first indication of its kind, after two double-blind trials; doses were slightly lower than those recommended for monotherapy in schizophrenia or bipolar disorder. Olanzapine and risperidone have several controlled clinical trials indicating the efficacy of both of these agents, generally at low doses. One trial of quetiapine suggested that it may not be effective in the treatment of unipolar, nonpsychotic depression. One open-label trial of ziprasidone indicated some efficacy. According to these results, aripiprazole, olanzapine, and risperidone are reasonable choices as augmentation agents, with only aripiprazole currently having an FDA indication for this use. Given the preliminary results, double-blind, placebo-controlled trials with quetiapine and ziprasidone are needed, as well as studies comparing atypical antipsychotic agents with traditional augmentation agents in the treatment of depression.
File Format	HTM / HTML
Issue Number	1
Volume Number	14
e-ISSN	15281145
Journal	Journal of Psychiatric Practice
Language	English
Publisher	Wolters Kluwer Health
Publisher Date	2008-01-01
Publisher Place	United States
Access Restriction	Subscribed
Subject Keyword	Discipline Psychiatry Antidepressive Agents Metabolism Therapeutic Use Antipsychotic Agents Pharmacology Depressive Disorder, Major Drug Therapy Benzodiazepines Clozapine Dibenzothiazepines Drug Synergism Drug Therapy, Combination Humans Piperazines Quetiapine Fumarate Risperidone Thiazoles Journal Article Review
Content Type	Text
Resource Type	Article

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in